医学
肿瘤科
化疗
食管鳞状细胞癌
中期分析
总体生存率
基底细胞
内科学
无进展生存期
癌
随机对照试验
作者
Ming-Ming He,Zhiqiang Wang,Lu Jin,Yuxian Bai,Teng Mao,Jun Wang,Qing-Xia Fan,X.-C. Zhang,Kuaile Zhao,Zhendong Chen,Shegan Gao,Jiancheng Li,Zhichao Fu,Kangsheng Gu,Zhihua Liu,Lin Wu,Xiaodong Zhang,Jifeng Feng,Zuoxing Niu,Yi Ba
出处
期刊：Med
[Elsevier BV]
日期：2024-06-12
卷期号：5 (9): 1137-1149.e3
被引量：5
标识
DOI：10.1016/j.medj.2024.05.008
摘要
The interim analysis of the randomized phase 3 ESCORT-1st study demonstrated significantly longer overall survival (OS) and progression-free survival (PFS) for camrelizumab-chemotherapy than placebo-chemotherapy in untreated advanced/metastatic esophageal squamous cell carcinoma (ESCC). Here, we present the final analysis of this study and investigate potential indicators associated with OS.
科研通智能强力驱动
Strongly Powered by AbleSci AI
YifanWang
剑指东方是为谁
田様
何时
zho
hyxu678
皖公网安备34019202002308
